Blood neurofilament light chain as a biomarker of MS disease activity and treatment response.

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response.

Publication date: Feb 08, 2019

To assess the value of blood neurofilament light chain (NfL) as a biomarker of recent, ongoing, and future disease activity and tissue damage and its utility to monitor treatment response in relapsing-remitting multiple sclerosis.

We measured NfL in blood samples from 589 patients with relapsing-remitting multiple sclerosis (from phase 3 studies of fingolimod vs placebo, FREEDOMS and interferon [IFN]-β-1a, TRANSFORMS) and 35 healthy controls and compared NfL levels with clinical and MRI-related outcomes.

At baseline, NfL levels (pg/mL) were higher in patients than in healthy controls (30.5 and 27.0 vs 16.9, p = 0.0001) and correlated with T2 lesion load and number of gadolinium-enhancing T1 lesions (p

Blood NfL levels are associated with clinical and MRI-related measures of disease activity and neuroaxonal damage and have prognostic value. Our results support the utility of blood NfL as an easily accessible biomarker of disease evolution and treatment response.

Kuhle, J., Kropshofer, H., Haering, D.A., Kundu, U., Meinert, R., Barro, C., Dahlke, F., Tomic, D., Leppert, D., and Kappos, L. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. 17336. 2019 Neurology.



Please signin to view all article content and metadata.


Leave a Comment